developing biomarkers and treatments for chronic joint diseases

 
Search
 
 
 « Back |   Home »  News & Reports  »  Latest News  »  All news  »  AnaMar Medical raises SEK 75 million in ...
 

AnaMar News

AnaMar Medical raises SEK 75 million in new financing

06 Nov 2008, Press release
The Swedish biotech company AnaMar Medical raises SEK 75 millon in a rights issue to finance continued development of its projects in chronic joint diseases. In a first step, the funds will finance a phase I study of a drug candidate developed for rheumatoid arthritis diseases.
Read more
Positive Phase I results for AMAP102
01 Jun 2010, News
New COMP ELISA Focus letter
26 Mar 2010, News
AMAP102, New Oral Cytokine Inhibitor to Treat Rheumatoid Arthritis - Phase 1 dosing completed , Results in Q1
01 Dec 2009, News
Company name change
01 Dec 2009, News
Innovation in Autoimmune Diagnostics - Visit AnaMar´s new website for INOVA´s Swedish customers!
30 Nov 2009, News
AnaMar News
> Latest News
> Press releases
> Sign up for RSS-feeds
Financial reports
> Annual report 2008
> Annual report 2007
> Annual report 2006
> Annual report 2005
> Annual report 2004
Publications
> Abstract ACR 2009
> Abstract EULAR 2009
> Abstract ACR 2007
Press images
> People
> Logo
© 2010, AnaMar AB, Kungsportsavenyn 22, SE-411 36, Göteborg, Sweden. Phone: +46 31 732 41 40, Fax: +46 31 732 41 49, info@anamar.com